Angina Pectoris Market

 

Key Highlights

 

• According to Martin et al. (2013), the prevalence of definite angina in Spain is higher in women (2.9%, 95% CI 2.2-3.7%) than in men (2.2%, 95% CI 1.6-2.9%). The prevalence of Confirmed Angina (CA) increased with age in both sexes (prevalence of 0.3% in those aged 40-49 years and 4% in those over 70 years).

 

• The disease epidemiology covered in the report provides historical as well as forecasted angina pectoris epidemiology [segmented as Total Prevalent Cases of   Angina Pectoris, Age- Specific Cases of Angina Pectoris, and Gender-specific Prevalence of Angina Pectoris in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Request for unlocking the CAGR of Angina Pectoris Market

 

DelveInsight's "Angina pectoris Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the angina pectoris, historical and forecasted epidemiology as well as the angina pectoris market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

The angina pectoris market report provides current treatment practices, emerging drugs, angina pectoris market share of the individual therapies, current and forecasted angina pectoris market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current angina pectoris treatment practice/algorithm, and Angina Pectoris unmet needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study Period: 2019–2032

 

Angina Pectoris Market Disease: Understanding and Treatment Algorithm

The DelveInsight’s angina pectoris market report gives a thorough understanding of angina pectoris by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. 

 

Angina pectoris or angina is pricking chest pain or discomfort as a result of decreased blood flow to the heart muscle. Angina is not a heart attack, but it is generally a warning sign for increased heart attack risk. Angina may be stable (develops during physical activity, lasts five minutes or less and is relieved with rest) or unstable (occurs during periods of rest, lasts longer, and symptoms may be more severe).

 

Angina Pectoris Treatment

The treatment landscape of angina involve both pharmacological and non-pharmacological intervention. Non-Pharmacological treatment option involves lifestyle changes, whereas pharmacological treatment involves: medication such as aspirin, statins, beta-blockers, calcium channel blockers, or nitrates, and surgical procedures like angioplasty and vascular stenting and Coronary artery bypass graft surgery (CABG).

 

Angina Pectoris Epidemiology

The angina pectoris epidemiology section provides insights about historical and current angina pectoris patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Martin et al. (2013), the prevalence of definite angina in Spain is higher in women (2.9%, 95% CI 2.2-3.7%) than in men (2.2%, 95% CI 1.6-2.9%). The prevalence of Confirmed Angina (CA) increased with age in both sexes (prevalence of 0.3% in those aged 40-49 years and 4% in those over 70 years).

 

• The disease epidemiology covered in the report provides historical as well as forecasted angina pectoris epidemiology [segmented as Total Prevalent Cases of   Angina Pectoris, Age- Specific Cases of Angina Pectoris, and Gender-specific Prevalence of Angina Pectoris in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country Wise- Angina pectoris Epidemiology

This section provides glimpse of the angina pectoris epidemiology in the United States, EU4 (Germany, Spain, Italy, France) and United Kingdom, and Japan

 

Angina Pectoris Drug Chapters

The drug chapter segment of the angina pectoris report encloses the detailed analysis of angina pectoris marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the angina pectoris clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Angina pectoris Marketed Drugs

Note: Detailed Current therapies assessment will be provided in the full report of angina pectoris 

 

Angina Pectoris Emerging Drugs

 

T-89 (Dantonic) (Tasly Pharmaceuticals)

T89, a 3-herb composition drug that improves microcirculation in and increase energy supply to the heart, and reduces blood viscosity in patients with chronic stable angina (A) has been shown to improve clinical outcomes in comparison to current anti-anginal drug (CAAD) such as β-blockers, Ca++ channel blockers or nitrates that only targets on coronary artery.

 

IMB-101 (Imbria Pharmaceuticals)

IMB-101 is a small molecule currently in development for the treatment of refractory angina by Imbria Pharmaceuticals. IMB-101 is a novel pFOX (partial fatty acid oxidation) inhibitor that is designed to optimize the use of fuels in the heart by partially shifting from using fat to using glucose, thereby resulting in the more efficient production of energy per molecule of oxygen consumed. This approach has been validated by trimetazidine (TMZ), a pFOX inhibitor used to treat angina in Europe since the 1970s. It is designed to have greater efficacy and a better benefit-risk profile than TMZ.

 

Note: Detailed emerging therapies assessment will be provided in the full report of angina pectoris 

 

Angina Pectoris Market Outlook

The treatment landscape of angina involve both pharmacological and non-pharmacological intervention. Non-Pharmacological treatment option involves lifestyle changes, whereas pharmacological treatment involves: medication such as aspirin, statins, beta-blockers, calcium channel blockers, or nitrates, and interventional procedures such as angioplasty and vascular stenting (In selected cases, following appropriate testing: Stenting is a procedure that uses balloons and/or stents, to open the blockage in the coronary arteries and improve blood flow to the heart) and Coronary artery bypass graft surgery (CABG) CABG increases blood flow to the heart by using a vein, or an artery from elsewhere in the body to divert blood flow around the area of narrowing or blockage in the coronary arteries of the heart.

 

Key players such as Tasly Pharmaceuticals, Imbria Pharmaceuticals along with few others are involved in developing therapies for angina pectoris.

 

According to DelveInsight, angina pectoris market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key findings

This section includes a glimpse of the angina pectoris market in 7MM.

 

The United States: Angina Pectoris Market Outlook

This section provides the total angina pectoris market size and market size by therapies in the United States.

 

EU4 and the UK: Angina Pectoris Market Outlook

The total angina pectoris market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: Angina Pectoris Market Outlook

The total angina pectoris market size and market size by therapies in Japan is also mentioned.

 

Analyst Commentary

 

• The pipeline of angina pectoris is very robust, many potential therapies are being investigated for the treatment of angina pectoris, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

 

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the angina pectoris market in the 7MM. Aside from that, the market size of angina pectoris may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

 

• The market growth of angina pectoris may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

 

Angina Pectoris Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the angina pectoris market or expected to get launched in the market during the study period 2019-2032. The analysis covers angina pectoris market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. 

 

Note: Detailed emerging therapies assessment will be provided in full report of angina pectoris.

 

Angina Pectoris Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses angina pectoris key players involved in developing targeted therapeutics.

 

Angina Pectoris Clinical Trials Development Activities

The analyses angina clinical trials report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for angina pectoris emerging therapies.

 

Reimbursement Scenario in Angina Pectoris 

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the angina pectoris domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or angina pectoris market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the Angina Pectoris unmet needs.

 

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the angina pectoris Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

 

Angina Pectoris Market Report Scope

• The report covers the descriptive overview of angina pectoris, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the angina pectoris epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for angina pectoris are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the angina pectoris market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The Patient-Based Angina Pectoris Market Forecasting report provides an edge while developing business strategies, by understanding trends shaping and driving the global angina pectoris market

 

Angina Pectoris Market Report Highlights

• In the coming years, the angina pectoris market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence angina pectoris R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for angina pectoris. The launch of emerging therapies will significantly impact the angina pectoris market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for angina pectoris 
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Angina Pectoris Report Insights

• Patient-Based Angina Pectoris Market Forecasting
• Therapeutic Approaches
• Angina Pectoris Pipeline Analysis
• Angina Pectoris Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

 

Angina Pectoris Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Angina Pectoris Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

 

Angina Pectoris Report Assessment

• Current Treatment Practices
• Angina Pectoris Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

 

Key Questions

 

Market Insights:

• What was the angina pectoris drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the angina pectoris total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest angina pectoris market size during the forecast period (2019-2032)?
• At what CAGR, the angina pectoris market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the angina pectoris market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the angina pectoris market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of angina pectoris?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• What is the historical angina pectoris patient pool in seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• What would be the forecasted patient pool of angina pectoris in seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about angina pectoris?
• Out of all 7MM countries, which country would have the highest prevalence population of angina pectoris during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the angina pectoris treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of angina pectoris in the USA, Europe, and Japan?
• What are the angina pectoris marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of angina pectoris?
• How many therapies are in-development by each company for angina pectoris treatment?
• How many are emerging therapies in mid-stage, and late stage of development for angina pectoris treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the angina pectoris therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for angina pectoris and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for angina pectoris?
• What are the global historical and forecasted markets of angina pectoris?

 

Reasons to buy

• The patient-based Angina Pectoris market forecasting report will help in developing business strategies by understanding trends shaping and driving the angina pectoris market
• Organize sales and marketing efforts by identifying the best opportunities for angina pectoris in the US, Europe (Germany, Spain, Italy, France and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the angina pectoris market
• To understand the future market competition in the angina pectoris market